THE EFFICACY OF RECOMBINANT ACTIVATED FACTOR VII (COAGIL VII) FOR TREATMENT HAEMORRHAGE AND HAEMOSTASIS DISORDES DURING THORACIC AORTA OPERATIONS

Goal: to evaluate the efficacy and safety of domestic (home-produced) recombinant factor VIIa (Coagil VII) for massive bleeding and haemostasis disordes treatment in thoracic aorta surgery. Methods. 82 patients undergoing surgery on thoracic aorta with cardiopulmonary bypass and circulatory arrest s...

Full description

Saved in:
Bibliographic Details
Main Authors: N. A. TREKOVA, D. A. GUSKOV, A. V. GONCHAROVA, B. A. AKSELROD
Format: Article
Language:Russian
Published: New Terra Publishing House 2019-07-01
Series:Вестник анестезиологии и реаниматологии
Subjects:
Online Access:https://www.vair-journal.com/jour/article/view/333
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1839581196312379392
author N. A. TREKOVA
D. A. GUSKOV
A. V. GONCHAROVA
B. A. AKSELROD
author_facet N. A. TREKOVA
D. A. GUSKOV
A. V. GONCHAROVA
B. A. AKSELROD
author_sort N. A. TREKOVA
collection DOAJ
description Goal: to evaluate the efficacy and safety of domestic (home-produced) recombinant factor VIIa (Coagil VII) for massive bleeding and haemostasis disordes treatment in thoracic aorta surgery. Methods. 82 patients undergoing surgery on thoracic aorta with cardiopulmonary bypass and circulatory arrest s were divided in 3 groups. The 1 group included 27 patients with uncomplicated operations, moderate hemorrhage and standart protocol hemostasis management after cardiopulmonary bypass. In 2 group of 26 patients with massive hemorrhage the thrombocytes were used for treatment. In 3 main group (29 patients) with continious bleeding Coagil VII was used additionally. Results. Coagil-VII induction in dose 37–100 mcg/kg was accompanied by prominent decreasing of wound bleeding in 20–25 min, that it allowed to perform sternoraphia. The volume of transfused erythrocytes , fresh frozen plasma and postoperative blood loss were less in comparison with control group and patients where the platelets were used. There were no any complications after Coagil VII induction. Analysis of the hemostasis indices showed decrease of APTT by 13%, PTT by 17% and MNO by 36% after Coagil VII induction. Conclusion. The domestic recombinant factor VIIa (Coagil VII) in dose 66 ± 19,5 mcg/kg is an effective and safe medicine for bleeding and hаemostasis desordes treatment in the patients undergoing aortic surgery
format Article
id doaj-art-e9f1c6decdda4d82a0e70174b34a01f1
institution Matheson Library
issn 2078-5658
2541-8653
language Russian
publishDate 2019-07-01
publisher New Terra Publishing House
record_format Article
series Вестник анестезиологии и реаниматологии
spelling doaj-art-e9f1c6decdda4d82a0e70174b34a01f12025-08-04T10:20:46ZrusNew Terra Publishing HouseВестник анестезиологии и реаниматологии2078-56582541-86532019-07-01163253210.21292/2078-5658-2019-16-3-25-31312THE EFFICACY OF RECOMBINANT ACTIVATED FACTOR VII (COAGIL VII) FOR TREATMENT HAEMORRHAGE AND HAEMOSTASIS DISORDES DURING THORACIC AORTA OPERATIONSN. A. TREKOVA0D. A. GUSKOV1A. V. GONCHAROVA2B. A. AKSELROD3B. V. Petrovsky Russian Research Surgery CenterB. V. Petrovsky Russian Research Surgery CenterB. V. Petrovsky Russian Research Surgery CenterB. V. Petrovsky Russian Research Surgery CenterGoal: to evaluate the efficacy and safety of domestic (home-produced) recombinant factor VIIa (Coagil VII) for massive bleeding and haemostasis disordes treatment in thoracic aorta surgery. Methods. 82 patients undergoing surgery on thoracic aorta with cardiopulmonary bypass and circulatory arrest s were divided in 3 groups. The 1 group included 27 patients with uncomplicated operations, moderate hemorrhage and standart protocol hemostasis management after cardiopulmonary bypass. In 2 group of 26 patients with massive hemorrhage the thrombocytes were used for treatment. In 3 main group (29 patients) with continious bleeding Coagil VII was used additionally. Results. Coagil-VII induction in dose 37–100 mcg/kg was accompanied by prominent decreasing of wound bleeding in 20–25 min, that it allowed to perform sternoraphia. The volume of transfused erythrocytes , fresh frozen plasma and postoperative blood loss were less in comparison with control group and patients where the platelets were used. There were no any complications after Coagil VII induction. Analysis of the hemostasis indices showed decrease of APTT by 13%, PTT by 17% and MNO by 36% after Coagil VII induction. Conclusion. The domestic recombinant factor VIIa (Coagil VII) in dose 66 ± 19,5 mcg/kg is an effective and safe medicine for bleeding and hаemostasis desordes treatment in the patients undergoing aortic surgeryhttps://www.vair-journal.com/jour/article/view/333recombinant activated factor viicoagil viiascending aortic and aortic arch surgeryhemostasis
spellingShingle N. A. TREKOVA
D. A. GUSKOV
A. V. GONCHAROVA
B. A. AKSELROD
THE EFFICACY OF RECOMBINANT ACTIVATED FACTOR VII (COAGIL VII) FOR TREATMENT HAEMORRHAGE AND HAEMOSTASIS DISORDES DURING THORACIC AORTA OPERATIONS
Вестник анестезиологии и реаниматологии
recombinant activated factor vii
coagil vii
ascending aortic and aortic arch surgery
hemostasis
title THE EFFICACY OF RECOMBINANT ACTIVATED FACTOR VII (COAGIL VII) FOR TREATMENT HAEMORRHAGE AND HAEMOSTASIS DISORDES DURING THORACIC AORTA OPERATIONS
title_full THE EFFICACY OF RECOMBINANT ACTIVATED FACTOR VII (COAGIL VII) FOR TREATMENT HAEMORRHAGE AND HAEMOSTASIS DISORDES DURING THORACIC AORTA OPERATIONS
title_fullStr THE EFFICACY OF RECOMBINANT ACTIVATED FACTOR VII (COAGIL VII) FOR TREATMENT HAEMORRHAGE AND HAEMOSTASIS DISORDES DURING THORACIC AORTA OPERATIONS
title_full_unstemmed THE EFFICACY OF RECOMBINANT ACTIVATED FACTOR VII (COAGIL VII) FOR TREATMENT HAEMORRHAGE AND HAEMOSTASIS DISORDES DURING THORACIC AORTA OPERATIONS
title_short THE EFFICACY OF RECOMBINANT ACTIVATED FACTOR VII (COAGIL VII) FOR TREATMENT HAEMORRHAGE AND HAEMOSTASIS DISORDES DURING THORACIC AORTA OPERATIONS
title_sort efficacy of recombinant activated factor vii coagil vii for treatment haemorrhage and haemostasis disordes during thoracic aorta operations
topic recombinant activated factor vii
coagil vii
ascending aortic and aortic arch surgery
hemostasis
url https://www.vair-journal.com/jour/article/view/333
work_keys_str_mv AT natrekova theefficacyofrecombinantactivatedfactorviicoagilviifortreatmenthaemorrhageandhaemostasisdisordesduringthoracicaortaoperations
AT daguskov theefficacyofrecombinantactivatedfactorviicoagilviifortreatmenthaemorrhageandhaemostasisdisordesduringthoracicaortaoperations
AT avgoncharova theefficacyofrecombinantactivatedfactorviicoagilviifortreatmenthaemorrhageandhaemostasisdisordesduringthoracicaortaoperations
AT baakselrod theefficacyofrecombinantactivatedfactorviicoagilviifortreatmenthaemorrhageandhaemostasisdisordesduringthoracicaortaoperations
AT natrekova efficacyofrecombinantactivatedfactorviicoagilviifortreatmenthaemorrhageandhaemostasisdisordesduringthoracicaortaoperations
AT daguskov efficacyofrecombinantactivatedfactorviicoagilviifortreatmenthaemorrhageandhaemostasisdisordesduringthoracicaortaoperations
AT avgoncharova efficacyofrecombinantactivatedfactorviicoagilviifortreatmenthaemorrhageandhaemostasisdisordesduringthoracicaortaoperations
AT baakselrod efficacyofrecombinantactivatedfactorviicoagilviifortreatmenthaemorrhageandhaemostasisdisordesduringthoracicaortaoperations